ArticleBritish journal of clinical pharmacology2017
Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study.
Article in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review.BMJ open respiratory research · 2020Pooled it
- Pooled it
- Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study.Advances in therapy · 2026Article
- Determinants of pneumonia among adult asthmatic patients attending public hospitals in Awi Zone, Northwest Ethiopia: A case control study.SAGE open medicine · 2026Article
- Observational
- Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer.Journal of pharmaceutical health care and sciences · 2024Article
- Article
- Article
- Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024Review
- Neutrophil to lymphocyte ratio in pediatric patients with asthmatic exacerbation and community-acquired pneumonia.BMC pediatrics · 2023Article
- Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma.Tuberculosis and respiratory diseases · 2023Article
- The role of the respiratory microbiome in asthma.Frontiers in allergy · 2023Review
- Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control.European clinical respiratory journal · 2023Review
- Severe disseminated primary varicella in a patient on long term inhaled corticosteroids.Respirology case reports · 2022Article
- Risk of pneumonia in asthmatic children using inhaled corticosteroids: a nested case-control study in a birth cohort.BMJ open · 2022Article
- Human matters in asthma: Considering the microbiome in pulmonary health.Frontiers in pharmacology · 2022Review
- Risk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study.Allergy, asthma & immunology research · 2021Review
- Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics.Cytokine & growth factor reviews · 2021Review
- Inhaled Corticosteroids Use and Risk of Invasive Pneumococcal Disease in a Population-based Study.Annals of the American Thoracic Society · 2020Article
- Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.The journal of allergy and clinical immunology. In practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimStudies have linked the use of inhaled corticosteroids (ICSs) to excess pneumonia risk in chronic obstructive pulmonary disease patients. The risk in asthma patients remains unclear. The objective of the present study was to examine the risk of pneumonia with ICSs in asthma patients aged 12-35 years.
methodsWe formed a cohort of asthma patients treated from 1990 to 2007 using Quebec health insurance databases. Subjects were considered currently exposed if they had had an ICS dispensed within the 60 days prior to their pneumonia index event or matched person-moment. Secondary analyses investigated the risk of pneumonia according to ICS dose and type. Rate ratios (RRs) and rate differences (RDs) were both estimated through a quasi-cohort approach.
resultsThe cohort included 152 412 subjects, of whom 1928 had a pneumonia event during follow-up. There was an increased risk of pneumonia associated with current use of ICSs [RR 1.83; 95% confidence interval (CI) 1.57, 2.14] or an excess risk of 1.44 cases per 1000 person-years (RD 1.44; 95% CI 1.03, 1.85). There was an excess pneumonia risk with low doses (RR 1.60; 95% CI 1.06, 2.45), moderate doses (RR 1.53; 95% CI 1.12, 2.08) and high doses (RR 1.96; 95% CI 1.64, 2.34) of ICSs, and with budesonide (RR 2.67; 95% CI 2.05, 3.49) and fluticasone (RR 1.93; 95% CI 1.58, 2.36), specifically relative to no use. When accounting for potential protopathic bias, the risk with current use of ICSs was attenuated (RR 1.48; 95% CI 1.22, 1.78).
conclusionICS use in asthma patients appears to be associated with an increased risk of pneumonia and is present for both budesonide and fluticasone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.